DelveInsight's "INBRIJA Market Size, Forecast, and Market Insight Report" highlights the details around INBRIJA, which ...

Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here’s what investors should know. AbbVie beat analysts’ revenue expectations by 1.9% last ...

AbbVie (NYSE:ABBV) is scheduled to announce its earnings on Friday, April 25, 2025. Currently, the company holds a market capitalization of $307 billion. Over the past twelve months, AbbVie ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...

I'll start by comparing the revenue growth rates of AbbVie and Sanofi, then move on to discuss how often these two leaders in the autoimmune disease treatment market beat Wall Street analysts ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the theft of trade secrets. Genmab has vowed to “vigorously defend ...

NORTH CHICAGO, Ill., Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable May ...

09:30 EST AbbVie (ABBV) seeing ‘significant advancements’ across entire pipeline Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Alvin Chan / SOPA Images / LightRocket via Getty Images Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.